Vertex Pharmaceuticals Inc / MaVRTX
Price (close)
$522.38
Market cap
$132.4B
P/E
30.1x
Revenue (TTM)
$12.6B
Net income
$4.4B
Dividend yield
—
1-year total return
36.8%
Net margin
35.0%
Revenue growth
10.2%
Debt / equity
—
What Vertex Pharmaceuticals Inc / Ma does.
No business description on file yet.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $6.2B | $7.6B | $8.9B | $9.9B | $11.0B | $12.0B |
| Net income | $2.7B | $2.3B | $3.3B | $3.6B | -$535.6M | $4.0B |
| Free cash flow | $3.0B | $2.4B | $3.9B | $3.3B | -$790.3M | $3.2B |
More on VRTX.
- Vertex Pharmaceuticals Inc / Ma summary
- Vertex Pharmaceuticals Inc / Ma financial statements
- Vertex Pharmaceuticals Inc / Ma key metrics
- Vertex Pharmaceuticals Inc / Ma health scores and style box
- Vertex Pharmaceuticals Inc / Ma earnings
- Vertex Pharmaceuticals Inc / Ma dividends
- Vertex Pharmaceuticals Inc / Ma valuation
- Vertex Pharmaceuticals Inc / Ma ownership and insiders
- Vertex Pharmaceuticals Inc / Ma peers
Figures from Vertex Pharmaceuticals Inc / Ma's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.